HawkCell Raises €5M in Series A Financing
Summary
The company intends to use the funds to scale up its business, enhance its ongoing efforts to elevate animal imaging, and drive its expansion into the North American pet market. Led by CEO Alexis Girin, HawkCell specializes in healthtech innovation in veterinary care and preclinical research with its magnetic resonance imaging (MRI) technology. At the core its product line is a proprietary, patented system integrating advanced hardware and software solutions, delivering rapid, accurate, and quantitative analyses for veterinarians and for the in vivo assessment of drug candidates and medical devices. HawkCell’s expertise spans an extensive range of fields including neurology, cardiology, gastrointestinal, musculoskeletal disorders, inflammation, oncology, metabolic diseases, and biocompatibility evaluations. Commenting on the news, Alexis Girin said: “We are thrilled to have the support of MIG Capital, a highly experienced venture fund led by entrepreneurs with a legacy of funding deep tech and life sciences breakthroughs, which shares our mission to narrow the gap between human and veterinary medicine.“